{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:58:25Z","timestamp":1781719105206,"version":"3.54.5"},"reference-count":32,"publisher":"Norwegian Medical Association","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"published-print":{"date-parts":[[2013,10,1]]},"DOI":"10.4045\/tidsskr.12.1106","type":"journal-article","created":{"date-parts":[[2014,1,10]],"date-time":"2014-01-10T10:07:49Z","timestamp":1389348469000},"page":"1946-50","source":"Crossref","is-referenced-by-count":1,"title":["Prim\u00e6r myelofibrose \u2013 patogenese, diagnostikk og behandling"],"prefix":"10.4045","volume":"133","author":[{"given":"Waleed","family":"Ghanima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e5var","family":"Knutsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Delabie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ystein","family":"Bruserud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14\u2009\u2013\u200922. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17882280&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038\/sj.leu.2404955","DOI":"10.1038\/sj.leu.2404955"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"James C, Ugo V, Le Cou\u00e9dic JP et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15793561&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1038\/nature03546","DOI":"10.1038\/nature03546"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J\u00a0Clin Oncol 2011; 29: 573\u2009\u2013\u200982. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21220604&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1200\/JCO.2010.29.8711","DOI":"10.1200\/JCO.2010.29.8711"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Tefferi A. How I treat myelofibrosis. Blood 2011; 117: 3494\u2009\u2013\u2009504. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21200024&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1182\/blood-2010-11-315614","DOI":"10.1182\/blood-2010-11-315614"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Ghanima W, Junker P, Hasselbalch HC et al. Fibroproliferative activity in patients with immune thrombocytopenia (ITP) treated with thrombopoietic agents. Br J Haematol 2011; 155: 248\u2009\u2013\u200955. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21902682&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1365-2141.2011.08845.x","DOI":"10.1111\/j.1365-2141.2011.08845.x"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Kuter DJ, Bain B, Mufti G et al. Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol 2007; 139: 351\u2009\u2013\u200962. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17910625&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1365-2141.2007.06807.x","DOI":"10.1111\/j.1365-2141.2007.06807.x"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Mesa RA, Silverstein MN, Jacobsen SJ et al. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976\u2009\u2013\u20091995. Am J Hematol 1999; 61: 10\u2009\u2013\u20095. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10331505&dopt=Abstract","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Johansson P, Kutti J, Andr\u00e9asson B et al. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of G\u00f6teborg, Sweden, during 1983\u2009\u2013\u200999. J\u00a0Intern Med 2004; 256: 161\u2009\u2013\u20095. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15257729&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1365-2796.2004.01357.x","DOI":"10.1111\/j.1365-2796.2004.01357.x"},{"key":"ref=9","unstructured":"Kreftregisteret. www.kreftregisteret.no\/no\/ (25.6.2013)."},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Barbui T, Barosi G, Birgegard G et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J\u00a0Clin Oncol 2011; 29: 761\u2009\u2013\u200970. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21205761&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1200\/JCO.2010.31.8436","DOI":"10.1200\/JCO.2010.31.8436"},{"key":"ref=11","unstructured":"Thiele J, Kvasnicka HM, Facchetti F et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005; 90: 1128\u2009\u2013\u200932. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16079113&dopt=Abstract"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Wilkins BS, Erber WN, Bareford D et al. Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Blood 2008; 111: 60\u2009\u2013\u200970. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17885079&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1182\/blood-2007-05-091850","DOI":"10.1182\/blood-2007-05-091850"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Thiele J, Kvasnicka HM, Zankovich R et al. Clinical and morphological criteria for the diagnosis of prefibrotic idiopathic (primary) myelofibrosis. Ann Hematol 2001; 80: 160\u2009\u2013\u20095. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11320901&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007\/s002770000278","DOI":"10.1007\/s002770000278"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Barbui T, Thiele J, Passamonti F et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol 2011; 29: 3179\u2009\u2013\u200984. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21747083&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1200\/JCO.2010.34.5298","DOI":"10.1200\/JCO.2010.34.5298"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Pardanani AD, Levine RL, Lasho T et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472\u2009\u2013\u20096. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16868251&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1182\/blood-2006-04-018879","DOI":"10.1182\/blood-2006-04-018879"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Cervantes F, Dupriez B, Pereira A et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895\u2009\u2013\u2009901. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18988864&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1182\/blood-2008-07-170449","DOI":"10.1182\/blood-2008-07-170449"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Kiladjian JJ, Cervantes F, Leebeek FW et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 2008; 111: 4922\u2009\u2013\u20099. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18250227&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1182\/blood-2007-11-125328","DOI":"10.1182\/blood-2007-11-125328"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Passamonti F, Cervantes F, Vannucchi AM et al. A\u00a0dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20008785&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1182\/blood-2009-09-245837","DOI":"10.1182\/blood-2009-09-245837"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Gangat N, Caramazza D, Vaidya R et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392\u2009\u2013\u20097. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21149668&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1200\/JCO.2010.32.2446","DOI":"10.1200\/JCO.2010.32.2446"},{"key":"ref=20","unstructured":"Nordic guidelines on the diagnosis and treatment of patients with myelproliferative neoplasms 2013. www.nmpn.org\/index.shtml (25.6.2013)."},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"McLornan DP, Mead AJ, Jackson G et al. Allogeneic stem cell transplantation for myelofibrosis in 2012. Br J Haematol 2012; 157: 413\u2009\u2013\u200925. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22463701&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1365-2141.2012.09107.x","DOI":"10.1111\/j.1365-2141.2012.09107.x"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Huang J, Tefferi A. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol 2009; 83: 154\u2009\u2013\u20095. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19366369&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1600-0609.2009.01266.x","DOI":"10.1111\/j.1600-0609.2009.01266.x"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Cervantes F, Alvarez-Larr\u00e1n A, Domingo A et al. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. Br J Haematol 2005; 129: 771\u2009\u2013\u20095. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15953003&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1111\/j.1365-2141.2005.05524.x","DOI":"10.1111\/j.1365-2141.2005.05524.x"},{"key":"ref=24","doi-asserted-by":"crossref","unstructured":"Marchetti M, Barosi G, Balestri F et al. Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial. J Clin Oncol 2004; 22: 424\u2009\u2013\u200931. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14752066&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1200\/JCO.2004.08.160","DOI":"10.1200\/JCO.2004.08.160"},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"Mesa RA, Steensma DP, Pardanani A et al. A\u00a0phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003; 101: 2534\u2009\u2013\u200941. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12517815&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1182\/blood-2002-09-2928","DOI":"10.1182\/blood-2002-09-2928"},{"key":"ref=26","doi-asserted-by":"crossref","unstructured":"Mesa RA, Yao X, Cripe LD et al. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood 2010; 116: 4436\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20651074&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1182\/blood-2010-05-287417","DOI":"10.1182\/blood-2010-05-287417"},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"Silver RT, Vandris K, Goldman JJ. Recombinant interferon-? may retard progression of early primary myelofibrosis: a preliminary report. Blood 2011; 117: 6669\u2009\u2013\u200972. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21518929&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1182\/blood-2010-11-320069","DOI":"10.1182\/blood-2010-11-320069"},{"key":"ref=28","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Trillos A, Gaya A, Maffioli M et al. Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients. Ann Hematol 2010; 89: 1233\u2009\u2013\u20097. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20567824&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007\/s00277-010-1019-9","DOI":"10.1007\/s00277-010-1019-9"},{"key":"ref=29","doi-asserted-by":"crossref","unstructured":"Tefferi A, Mesa RA, Nagorney DM et al. Splenectomy in myelofibrosis with myeloid metaplasia: a\u00a0single-institution experience with 223 patients. Blood 2000; 95: 2226\u2009\u2013\u200933. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10733489&dopt=Abstract","DOI":"10.1182\/blood.V95.7.2226.007k19_2226_2233"},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"Mesa RA, Nagorney DS, Schwager S et al. Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic. Cancer 2006; 107: 361\u2009\u2013\u200970. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16770787&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002\/cncr.22021","DOI":"10.1002\/cncr.22021"},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"Verstovsek S, Mesa RA, Gotlib J et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799\u2009\u2013\u2009807. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22375971&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa1110557","DOI":"10.1056\/NEJMoa1110557"},{"key":"ref=32","doi-asserted-by":"crossref","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787\u2009\u2013\u200998. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=22375970&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa1110556","DOI":"10.1056\/NEJMoa1110556"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":[],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:36:11Z","timestamp":1781717771000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2013\/10\/oversiktsartikkel\/primaer-myelofibrose-patogenese-diagnostikk-og-behandling"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,1]]},"references-count":32,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2013,10,1]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.12.1106","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,1]]}}}